BioNTech Expands Supervisory Board to 8 Members, Elects 2 New Experts

BioNTech SE held its Annual General Meeting, where shareholders approved all proposed resolutions, with 92% of the share capital represented. A key approval included expanding the Supervisory Board from six to eight members to add further expertise, aligning with the company's strengthened focus on its late-stage oncology pipeline. Prof. Iris Löw-Friedrich and Dr. Susanne Schaffert were elected as new members, bringing extensive experience in clinical development, oncology, sales, and commercialization. Additionally, the mandates of existing Supervisory Board members Helmut Jeggle, Prof. Anja Morawietz, and Prof. Rudolf Staudigl were extended, with Helmut Jeggle re-elected as Chairman.